Certara Reports First Quarter 2022 Financial Results

Written by Customer Service on May 5, 2022. Posted in Earnings Releases And Operating Results.

PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2022. First Quarter Highlights: Revenue was $81.6 million, compared to $66.7 million in the first quarter of 2021, representing growth of 22% over the first quarter of 2021. Excluding Pinnacle 21, revenue was $75.6 million, representing growth of 13% over the first quarter of 2021. Net income was $2.2 million, compared to net income of $1.1 million in the first quarter of 2021, representing growth of 110% over the first quarter of 2021. Adjusted EBITDA was $27.7 million, compared to $23.9 million in the first quarter of 2021, representing growth of 16% over the first quarter of 2021. “Certara delivered strong revenue growth in the first quarter,...

Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Written by Customer Service on May 5, 2022. Posted in Earnings Releases And Operating Results.

EXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2022. “We continue to preserve cash while actively pursuing new development or commercial-stage assets for Idera’s portfolio,” stated Vincent Milano, Idera’s Chief Executive Officer. “We also continue to work with JMP Securities, a Citizens Company, our current partner and advisor on business development activities, to explore additional strategic alternatives for the Company.” First Quarter Financial Results Our cash position as of March 31, 2022 was $28.0 million. Based on our current operating plan, we anticipate that our current cash and cash equivalents will fund our operations through the one-year period...

Paycor Announces Third Quarter Fiscal Year 2022 Financial Results

Written by Customer Service on May 5, 2022. Posted in Earnings Releases And Operating Results.

Q3 Total revenue of $122.6 million, an increase of 23% year-over-year Raises FY’22 revenue guidance to $421-$422 million, an increase of approximately 20% year-over-year at the top end of the range CINCINNATI, May 05, 2022 (GLOBE NEWSWIRE) — Paycor HCM, Inc. (Nasdaq: PYCR) (“Paycor”), a leading provider of human capital management (“HCM”) software, today announced financial results for the third quarter of fiscal year 2022, which ended March 31, 2022. “Paycor delivered impressive revenue growth of 23% year-over-year, fueled by continued strong client growth,” said Raul Villar, Jr., Chief Executive Officer of Paycor. “Demand remains robust for modern cloud-based HCM solutions and our differentiated platform purpose-built for leaders and configured by industry continues to resonate in the market.” “We further enhanced our HCM...

Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

Written by Customer Service on May 5, 2022. Posted in Earnings Releases And Operating Results.

On track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC) in June 2022; topline results anticipated in 4Q 2022 On track to initiate Phase 1b clinical trial of ALRN-6924 in patients with p53-mutated ER+/HER2- neoadjuvant breast cancer in 2Q 2022; initial interim results anticipated in 4Q 2022 Company to host a virtual investor event on May 19th to discuss ALRN-6924’s revolutionary potential as the first precision medicine-based supportive care drug, the landscape of chemotherapy-induced toxicities, and the company’s planned 2022 data readouts Cash, cash equivalents, and investments as of March 31, 2022, expected to fund operations into the fourth quarter of 2023 BOSTON, May 05, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN),...

Apollo Tactical Income Fund Inc. Declares May 2022 Monthly Distribution of $0.090 Per Share

Written by Customer Service on May 5, 2022. Posted in Dividend Reports And Estimates.

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) — (NYSE: AIF) – Apollo Tactical Income Fund Inc. (the “Fund”) today announced the declaration of its distribution for the month of May 2022 of $0.090 per common share, payable on the date noted below. The following dates apply to the declared distribution: Ex-Date: May 19, 2022Record Date: May 20, 2022Payment Date: May 31, 2022Per Share Amount: $0.090 Apollo Contact Information: Product Literature877-864-4834 InvestorsElizabeth BesenInvestor Relations ManagerApollo Global Management, Inc.212-822-0625ebesen@apollo.com Forward-Looking Statements This press release may contain statements that are forward looking, as that term is defined by the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules, regulations and releases. These statements...

Apollo Senior Floating Rate Fund Inc. Declares May 2022 Monthly Distribution of $0.085 Per Share

Written by Customer Service on May 5, 2022. Posted in Dividend Reports And Estimates.

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) — (NYSE: AFT) – Apollo Senior Floating Rate Fund Inc. (the “Fund”) today announced the declaration of its distribution for the month of May 2022 of $0.085 per common share, payable on the date noted below. The following dates apply to the declared distribution: Ex-Date: May 19, 2022Record Date: May 20, 2022Payment Date: May 31, 2022Per Share Amount: $0.085 Apollo Contact Information: Product Literature877-864-4834 InvestorsElizabeth BesenInvestor Relations ManagerApollo Global Management, Inc.212-822-0625ebesen@apollo.com Forward-Looking Statements This press release may contain statements that are forward looking, as that term is defined by the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules, regulations and releases. These...

Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results

Written by Customer Service on May 5, 2022. Posted in Earnings Releases And Operating Results.

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) — Cellectis S.A. (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company and a majority-owned subsidiary of Cellectis, released today financial results for Calyxt’s first quarter ended March 31, 2022. The contents of Calyxt’s announcement are included below. “The first quarter of 2022 marked a period of instrumental advancement across several critical areas for Calyxt. As a result of our expanded customer engagement, the breadth and depth of our business development discussions have grown, demonstrated by the 28 molecules identified by potential customers that we have evaluated for...

NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results

Written by Customer Service on May 5, 2022. Posted in Earnings Releases And Operating Results.

Initiated Phase 1/1b clinical trial of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab), for the treatment of patients with advanced solid tumors Presented preclinical research for NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, NGM831 and NGM438, a LAIR1 antagonist product candidate, at the American Association for Cancer Research (AACR) 2022 Annual Meeting SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the quarterly period ended March 31, 2022. “We are pleased with the progress that we have made to...

CareTrust REIT Announces First Quarter 2022 Operating Results

Written by Customer Service on May 5, 2022. Posted in Earnings Releases And Operating Results.

Conference Call Scheduled for Friday, May 6, 2022 at 1:00 pm ET SAN CLEMENTE, Calif., May 05, 2022 (GLOBE NEWSWIRE) — CareTrust REIT, Inc. (Nasdaq:CTRE) today reported operating results for the quarter ended March 31, 2022, as well as other recent events. For the quarter, CareTrust REIT reported: 95% of contractual rents collected; Net loss of $43.3 million and net loss per share of $0.45; Normalized FFO of $35.9 million, a 5.2% increase over the prior year, and normalized FFO per share of $0.37; Normalized FAD of $37.9 million, a 4.8% increase over the prior year, and normalized FAD per share of $0.39; and A quarterly dividend of $0.275 per share, representing a payout ratio of approximately 71% on normalized FAD. Key Operating Metrics CareTrust’s President and Chief Executive Officer, Dave Sedgwick, commented on the Company’s...

Alkami Announces First Quarter 2022 Financial Results

Written by Customer Service on May 5, 2022. Posted in Earnings Releases And Operating Results.

PLANO, Texas, May 05, 2022 (GLOBE NEWSWIRE) — Alkami Technology, Inc. (Nasdaq: ALKT) (“Alkami”), a leading cloud-based digital banking solutions provider for U.S. banks and credit unions, today announced results for its first quarter ending March 31, 2022. First Quarter 2022 Financial Highlights GAAP total revenue of $44.8 million, an increase of 35% compared to the year-ago quarter; GAAP gross margin of 55%, compared to 53% in the year-ago quarter; Non-GAAP gross margin of 58%, compared to 55% in the year-ago quarter; GAAP net loss of ($13.4) million, compared to ($10.9) million in the year-ago quarter; and Adjusted EBITDA loss of ($3.6) million, compared to ($6.1) million in the year-ago quarter. Comments on the News Alex Shootman, Chief Executive Officer, said, “In the first quarter, sales performance continued to thrive....

Day: May 5, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice